SEC Form 4 · accession 0001144204-15-047008
Armata Pharmaceuticals, Inc. · ARMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Scott Salka
Officer — Chief Executive Officer · Director
Period of report
Aug 5, 2015
Accepted (ET)
Aug 6, 2015 · 5:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921114
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.189 | Aug 5, 2015 | A | 19,985,810 | A | — | Aug 5, 2025 | Common Stock | 19,985,810 | 19,985,810 | D |
Explanation of responses
- F1Two-thirds of the shares underlying this option will vest and become exercisable upon AmpliPhi Bioscience Corporation's (the "Company") satisfaction of certain business goals. One-third of the shares underlying this option will vest and become exercisable in accordance with the following schedule: 25% of such shares shall vest on the one year anniversary of the start of Mr. Salka's employment with the Company, and thereafter 1/48th of such shares shall vest on each monthly anniversary of the start of Mr. Salka's employment with the Company.